Article
Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement
Author(s):
Bristol-Myers Squibb and Samsung BioLogics expand their manufacturing agreement to cover biologic medicines.
Bristol-Myers Squibb and Samsung BioLogics have expanded their existing manufacturing agreement, in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at Samsung's Incheon, China manufacturing site. Financial terms of the agreement are not disclosed.
Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance.
Source: Bristol-Myers Squibb
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
